Literature DB >> 19037987

Cardiomyopathy of unknown etiology: Barth syndrome unrecognized.

Robert T Sweeney1, Gregory J Davis, Jacqueline A Noonan.   

Abstract

This is a report of a child who died at 20 months from what was clinically thought to be cardiomyopathy of unknown etiology. Barth syndrome, an X-linked mitochondrial cardioskeletal myopathy, was diagnosed by genetic testing at autopsy. Barth syndrome presents in infancy or childhood with cardiomyopathy, hypotonia, growth delays, and cyclic neutropenia. Other associated laboratory findings can include hypocholesterolemia, relative monocytosis, low prealbumin, low plasma carnitine, and lactic acidosis. The classic echocardiogram finding is left ventricular noncompaction, although not always present. Until recently, the most reliable biochemical finding has been 3-methylglutaconic aciduria. However, quantitative analysis must be specifically requested for results to be reliable. Recently, a confirmatory tetralinoleoyl cardiolipin high-pressure liquid chromotography-tandem mass spectrometry blood test has become available. Genetic testing is also confirmatory and details the underlying mutation. Diagnosis is often missed or delayed and early diagnosis improves survival. The purpose of this case report is to encourage physicians to include Barth syndrome in the differential for cardiomyopathy of uncertain etiology in males, especially in the presence of growth delays, hypotonia, neutropenia, and/or family history of pediatric male death of unknown etiology.

Entities:  

Mesh:

Year:  2008        PMID: 19037987     DOI: 10.1111/j.1747-0803.2008.00226.x

Source DB:  PubMed          Journal:  Congenit Heart Dis        ISSN: 1747-079X            Impact factor:   2.007


  5 in total

1.  Barth syndrome diagnosed in the subclinical stage of heart failure based on the presence of lipid storage myopathy and isolated noncompaction of the ventricular myocardium.

Authors:  Atsuhito Takeda; Akira Sudo; Masafumi Yamada; Hirokuni Yamazawa; Gaku Izumi; Ichizo Nishino; Tadashi Ariga
Journal:  Eur J Pediatr       Date:  2011-09-20       Impact factor: 3.183

2.  Overexpression of human fatty acid transport protein 2/very long chain acyl-CoA synthetase 1 (FATP2/Acsvl1) reveals distinct patterns of trafficking of exogenous fatty acids.

Authors:  Elaina M Melton; Ronald L Cerny; Concetta C DiRusso; Paul N Black
Journal:  Biochem Biophys Res Commun       Date:  2013-10-08       Impact factor: 3.575

Review 3.  TAZ encodes tafazzin, a transacylase essential for cardiolipin formation and central to the etiology of Barth syndrome.

Authors:  Anders O Garlid; Calvin T Schaffer; Jaewoo Kim; Hirsh Bhatt; Vladimir Guevara-Gonzalez; Peipei Ping
Journal:  Gene       Date:  2019-10-21       Impact factor: 3.688

Review 4.  Successful management of Barth syndrome: a systematic review highlighting the importance of a flexible and multidisciplinary approach.

Authors:  Stacey Reynolds
Journal:  J Multidiscip Healthc       Date:  2015-07-29

5.  Left ventricular noncompaction (LVNC) and low mitochondrial membrane potential are specific for Barth syndrome.

Authors:  Agnieszka Karkucinska-Wieckowska; Joanna Trubicka; Bozena Werner; Katarzyna Kokoszynska; Magdalena Pajdowska; Maciej Pronicki; Elzbieta Czarnowska; Magdalena Lebiedzinska; Jolanta Sykut-Cegielska; Lidia Ziolkowska; Weronika Jaron; Anna Dobrzanska; Elzbieta Ciara; Mariusz R Wieckowski; Ewa Pronicka
Journal:  J Inherit Metab Dis       Date:  2013-01-30       Impact factor: 4.982

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.